Adherence to the new British Society for Rheumatology Psoriatic Arthritis guidelines for anti-tumour necrosis factor therapy

被引：0
|
作者：
Farquhar, K.
Reid, M.
Hanlon, S.
Perry, M. E.
机构：
[1] Royal Alexandra Hosp, Dept Rheumatol, Edmonton, AB, Canada
[2] Inverclyde Royal Hosp, Dept Rheumatol, Greenock, Scotland
来源：
SCOTTISH MEDICAL JOURNAL | 2015年 / 60卷 / 03期
关键词：
Psoriatic arthritis; biologic therapy;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E14 / E15
页数：2
相关论文
共 50 条
  • [31] Association between anti-tumour necrosis factor therapy and risk of ischaemic stroke in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registers-Rheumatoid Arthritis (BSRBR-RA)
    Low, Audrey S. L.
    Lunt, Mark
    Mercer, Louise K.
    Galloway, James B.
    Davies, Rebecca
    Watson, Kath D.
    Symmons, Deborah P.
    Dixon, William G.
    Hyrich, Kimme L.
    LANCET, 2013, 381 : 66 - 66
  • [32] Anti-tumour necrosis factor α therapy modulates ghrelin in patients with severe rheumatoid arthritis
    Gonzalez-Gay, M. A.
    Garcia-Unzueta, M. T.
    Berja, A.
    Vazquez-Rodriguez, T. R.
    Gonzalez-Juanatey, C.
    de Matias, J. M.
    Martin, J.
    Dessein, P. H.
    Llorca, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) : 1644 - 1646
  • [33] Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal
    Braun, J
    Sieper, J
    van der Heijde, D
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (10) : 1023 - 1024
  • [34] Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis
    Choy, E
    CYTOKINE, 2004, 28 (4-5) : 158 - 161
  • [35] Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients:: results from the South Swedish Arthritis Treatment Group register
    Kristensen, L. E.
    Gulfe, A.
    Saxne, T.
    Geborek, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) : 364 - 369
  • [36] The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
    Harrold, Leslie R.
    Reed, George W.
    Kremer, Joel M.
    Curtis, Jeffrey R.
    Solomon, Daniel H.
    Hochberg, Marc C.
    Greenberg, Jeffrey D.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 430 - 436
  • [37] DRUG SURVIVAL OF SECOND BIOLOGIC DMARD THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: COMPARISON OF A SECOND ANTI-TUMOUR NECROSIS FACTOR WITH A SECOND NON-ANTI-TUMOUR NECROSIS FACTOR AFTER DISCONTINUATION OF A FIRST ANTI-TUMOUR NECROSIS FACTOR
    Wilke, Thomas
    Mueller, Sabrina
    Majer, Istvan
    Heisen, Marieke
    Fuchs, Andreas
    Maywald, Ulf
    RHEUMATOLOGY, 2016, 55 : 105 - 105
  • [38] Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
    Galloway, James B.
    Mercer, Louise K.
    Moseley, Alison
    Dixon, William G.
    Ustianowski, Andrew P.
    Helbert, Matthew
    Watson, Kath D.
    Lunt, Mark
    Hyrich, Kimme L.
    Symmons, Deborah Pm
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (02) : 229 - 234
  • [39] PATIENTS RECEIVING ANTI-TUMOUR NECROSIS FACTOR THERAPIES EXPERIENCE CLINICALLY IMPORTANT IMPROVEMENTS IN RHEUMATOID ARTHRITIS RELATED FATIGUE: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER
    Druce, Katie
    Jones, Gareth T.
    Macfarlane, Gary J.
    Basu, Neil
    RHEUMATOLOGY, 2014, 53 : 44 - 44
  • [40] Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis: what is the role of inflammation control?
    Roseman, C.
    Wallman, J. k
    Joud, A.
    Schelin, M. E. C.
    Einarsson, J. T.
    Lindqvist, E.
    Lampa, J.
    Kapetanovic, M. C.
    Olofsson, T.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2024, 53 (02) : 94 - 103
12345